The chronic obstructive pulmonary disease (COPD) therapy market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations (LABA/ICSFDCs)…
Non-alcoholic steatohepatitis (NASH) is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of…
Sjögren's syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with…
Implementation of vaccination programs has had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing…
The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…
Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant…
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells (RBCs) that distorts them into a sickle shape. This sickling leads to…
The pharmaceutical market for nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD), has the potential to become lucrative owing to the current lack of…
The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…
DRG Epidemiology’s coverage of atrial fibrillation comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of atrial fibrillation for…
Treatment for major depressive disorder (MDD) involves a range of safe and effective therapies, many of which are available as inexpensive generics. Agents for treating MDD span multiple drug…
The 2016 and 2017 FDA approvals of multiple immune checkpoint inhibitors for advanced bladder cancer have greatly altered the treatment landscape for this disease. The FDA’s (2020) and EC’s (…
Approximately 80% of rare diseases have a genetic etiology. Gene therapies hold the potential to transform the treatment of rare diseases and may provide a functional cure for some. However, these…
Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of approved agents and the disease’s relatively high prevalence…